Molecular solutions provider Vela Diagnostics has introduced two new next-generation sequencing (NGS)-based pan-cancer gene panels.

The panels include focused OncoKey SL 60 Plus Panel, and the comprehensive OncoKey SL 525 Plus Panel.

The panels are meant for the detection of DNA and RNA cancer biomarkers from formalin-fixed paraffin-embedded (FFPE) tissue specimens, for up to 64 samples in a single sequencing run.

The two pan-cancer gene panels will be able to detect multiple biomarkers in one assay with only 40 ng of nucleic acid.

Biomarkers that are detected by the panels include single nucleotide variations (SNVs), insertions/deletions (INDELs), copy number variations (CNVs), microsatellite instability (MSI), fusions, splice variants, oncogenic viruses and bacteria, as well as measuring the tumor mutation burden (TMB).

Vela Diagnostics’ European organisation managing director Dr Andreas Goertz said: “VELA’s OncoKey 60 and 525 Plus Panels represent an exciting development in precision medicine for cancer.

“These panels consist of clinically relevant genes of interest and were designed based on input from key opinion leaders in oncology, as well as references to professional guidelines, curated clinical trial and cancer databases.”

The panels use a highly automated sample-to-result approach to produce results from in less than 5 days with a requirement of 2.5 hours of hands-on time.

In addition, they offer high sample traceability, from automated sample extraction to data quality control.

Vela said that the panel workflows are designed to work with Illumina sequencing platforms, making them adaptable to existing lab situations.

Vela Diagnostics CEO and executive chairman Sam Dajani said: “Vela Diagnostics is planning to launch our OncoKey 60 and 525 Plus Panels in Q4 2022 in the USA and Asia Pacific.

“Using these panels on Vela Diagnostics’ automated workflow will reduce human error and minimize sample cross contamination which can be generated by using a manual workflow.

“In addition, our VELA Analytics solutions and services can identify and interpret genetic variants in tumours making it possible to provide actionable options for healthcare and research professionals quickly and accurately.”